Anavex Life Sciences (AVXL) 0.3600 $AVXL Anavex Reports

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 3:09 PM

Anavex Life Sciences (AVXL) 0.3600 $AVXL

Anavex Reports Fiscal Second Quarter 2015 Financial Results
M2 - Fri May 15, 11:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2015.

Anavex to Present at 2015 Marcum Conference on May 27th
GlobeNewswire - Wed May 13, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015 at 3:30 p.m. ET in the Winter Garden room at the Grand Hyatt New York.

Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
M2 - Thu Apr 23, 10:07AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a presentation titled "Potential applications of sigma-1 receptors in orphan indications," Dr. Missling will discuss the role of sigma-1 receptors in additional indications beyond Alzheimer's disease.

Anavex Life Sciences Analyst Coverage Initiated: Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Apr 23, 6:00AM CDT
Anavex Life Science Corp. (OTCMKTS: AVXL) was incorporated on January 23, 2004. The company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system diseases.

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain
M2 - Tue Apr 07, 9:43AM CDT
Report Further Validates Therapeutic Application of Proprietary Anavex Compounds in Multiple Neurological Diseases

Anavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
GlobeNewswire - Tue Apr 07, 7:47AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time through real-time in vivo imaging how microglial inflammation, which is involved in devastating neurodegenerative diseases, can be resolved by sigma-1 receptor activation. The role of sigma-1 receptor activation is to reduce the negative response caused by chronic microglia over-activation, which leads to widespread cell death and multiple neurodegenerative diseases, from brain injury to Alzheimer's disease.

Anavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer's Models at 2015 AD/PD(TM) Conference
GlobeNewswire - Mon Mar 23, 7:47AM CDT
ANAVEX 2-73 strong reversal of memory impairment in Alzheimer's disease model

Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS

MCB).

New Data on Two Anavex Alzheimer's Drugs to be Unveiled at AD/PD 2015
M2 - Fri Mar 20, 7:02AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's and other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce the upcoming presentation of new data for two of its Alzheimer's drug candidates, ANAVEX 2-73 and ANAVEX 3-71, at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2015).

Anavex to Participate in Phase 3 Clinical Trials Panel at AD/PD 2015
M2 - Tue Mar 17, 1:15PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's and other central nervous system (CNS) diseases, pain and various types of cancer, today announces that Christopher U. Missling, PhD, president and chief executive officer, will participate in a clinical trials podium discussion titled, "Is there a way to increase the chance of success in Phase 3?" at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2015). The panel takes place on March 22, 2015 at 13:45 local time in the Apollon room of the Nice Acropolis Convention Center in Nice, France.

Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board
M2 - Thu Mar 12, 10:52AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Jacqueline French, MD, FAAN, to the Company's Scientific Advisory Board. Dr. French is an award-winning, internationally recognized expert on epilepsy, new therapeutic interventions and clinical trial methodology.

Anavex to Present at Sigma-1 Receptors Symposium
M2 - Tue Mar 10, 12:47PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at 'The Physiopathology of Sigma-1 Receptors' symposium being held at the Nice Sophia Antipolis University in Nice, France. The scientific symposium takes place on March 17, 2015 and addresses the broad variety of potential applications of the sigma-1 receptor in neurodegenerative diseases, pain and cancer representing a new mode of action of functional proteins in the biological system. The neuroprotective action of the sigma-1 receptor and associated ligands may be explained by the novel mode of action of this unique molecular chaperone.

Anavex to Present at 27th Annual ROTH Conference on March 11th
GlobeNewswire - Tue Mar 03, 6:13AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 11:00 a.m. PT in Salon 2 at the Ritz Carlton in Dana Point, California. Investors may view Dr. Missling's presentation via live webcast on the ROTH website or access an archived version via Anavex.com.

Anavex Reports Fiscal First Quarter 2015 Financial Results
M2 - Thu Feb 19, 7:32AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bright Idea: Menu Covers Light Up Dining Spaces

Lighting Up Dinner Conversations You ever sit in a restaurant dim enough to make you question if even the chef can see in that darkness? Enter the MENU AID, a nifty brainchild straight out of Chula Vista, California. This invention brings a bright twist to our dining escapades, literally. Picture a menu cover that lights up like it's got its own little halo, solving the...

Vijit Chao Phraya 2026: Transforming Bangkok with Light

Bangkok's Night Sky Turns into an Artistic Canvas You think light shows are done and dusted? Think again. The Vijit Chao Phraya 2026 kicks off yet another spellbinding spectacle along the beloved river, turning Bangkok's waterline into an electrifying canvas of color and culture. For a month, from November 13 to December 13, this unique event unfolds across 19 different...

D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Daniel Wellington's 2026 Holiday Gift Guide Highlights

Personalized Gifts for the Holidays You ever try picking out a gift that screams 'I nailed it'? Daniel Wellington gets it, and this year's Holiday Gift Guide is their way of handing you the solution on a silver platter. It’s all about refining your choices to match the style and personality that make each person unique. Forget the generic socks; this guide is laying out...

Diwali Celebration in Chicago Honors Indian Community

Chicago's Diwali Tribute: Music, Dance, and Diversity Talk about spreading the glow! On November 13, 2026, Cook County Treasurer Maria Pappas is gearing up to throw a Diwali bash that'll light up Chicago's cultural landscape. Alongside Indian Consul General Dr. M. Anand Prakash, she's orchestrating a vibrant affair designed to spotlight Indian American community leaders...

Thanksgiving in Outer Banks: Unique Traditions Await

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

U-wifi Gains Charlie Vogt: Key Steps in 5G Expansion

Charlie Vogt Joins U-wifi: A Broadband Game Changer? There's a new player in town shaking things up, and he's no rookie. Charlie Vogt, five-time technology CEO and Managing Director at Bowen, is hopping onto U-wifi's board of directors. This isn't just about another corporate announcement; it's like adding a veteran quarterback to your expansion team. Vogt’s pedigree in...

Wiz Khalifa Ignites MJBizCon 2026 with Keynote and Music

An Icon in Cannabis Culture Hits the Stage When you mix business with pleasure, you get something like what MJBizCon's cooking up this year. Wiz Khalifa, the man with a knack for turning passion into profit, is jumping onto the stage—not just as a performer, but also as a keynote speaker. On December 2, attendees are in for a treat as he steps into a new spotlight at...

Balancing Rigor and Interests in Education: Insights

Education: A Balancing Act of Academics and Interests So here's the deal, folks. Education isn't just about hitting the textbooks and acing exams. It's a wild dance—balancing rigorous academics and the extracurricular hustle. Brent Reckman, the brains behind The Academy of Charter Schools in Westminster, Colorado, knows this orchestra well. In a feature with...

MyStation Disrupts Media Ownership, Empowers Creators

Changing the Game for Content Creators Never thought you'd see the day where you're not bowing down to broadcast giants? Well, here it is. MyStation's stepping into the ring, swinging hard at traditional media's big wigs, handing over the reins to anyone daring enough to build an audience. This launch can dish out a thrashing to those high walls keeping folks from owning...